Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 2,530,000 shares, an increase of 25.9% from the November 30th total of 2,010,000 shares. Currently, 8.2% of the company’s stock are short sold. Based on an average daily trading volume, of 328,900 shares, the days-to-cover ratio is presently 7.7 days.
Analyst Upgrades and Downgrades
TYRA has been the topic of a number of recent analyst reports. Oppenheimer lifted their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Friday, October 25th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $22.00 to $31.00 in a report on Friday, October 18th. Finally, HC Wainwright dropped their price objective on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $31.00.
Read Our Latest Research Report on Tyra Biosciences
Insider Activity at Tyra Biosciences
Institutional Trading of Tyra Biosciences
Institutional investors and hedge funds have recently modified their holdings of the company. HighVista Strategies LLC acquired a new stake in Tyra Biosciences during the second quarter worth $257,000. Franklin Resources Inc. bought a new stake in Tyra Biosciences in the third quarter valued at about $278,000. Valence8 US LP acquired a new position in Tyra Biosciences in the third quarter worth about $310,000. SG Americas Securities LLC bought a new position in Tyra Biosciences during the third quarter worth about $311,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Tyra Biosciences during the third quarter valued at approximately $333,000. 84.14% of the stock is currently owned by institutional investors.
Tyra Biosciences Stock Down 1.2 %
NASDAQ TYRA traded down $0.17 during midday trading on Monday, hitting $13.90. The company had a trading volume of 125,509 shares, compared to its average volume of 195,783. The firm has a fifty day simple moving average of $16.85 and a two-hundred day simple moving average of $19.39. Tyra Biosciences has a fifty-two week low of $11.24 and a fifty-two week high of $29.60. The stock has a market cap of $703.38 million, a price-to-earnings ratio of -8.63 and a beta of 1.01.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, equities analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current year.
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Recommended Stories
- Five stocks we like better than Tyra Biosciences
- Trading Stocks: RSI and Why it’s Useful
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- What is Put Option Volume?
- Micron: Why Now Is the Time to Be Brave
- What is an Earnings Surprise?
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.